[Featured Stock] Lunit Demonstrates AI Diagnostic Superiority with 55,000-Person Validation... Global Medical Community Rushes to Adopt AI

Lunit is showing strong performance. The news that it has revealed the world's first real-world data (RWD) research results where AI replaced doctors in actual medical practice appears to be influencing its stock price. The medical AI detected more cancers than doctors and drastically reduced reading time.

At 9:40 a.m. on the 2nd, Lunit was trading at 70,400 won, up 3.53% from the previous trading day.

Medical artificial intelligence (AI) company Lunit announced clinical real-world data (RWD) collected over about one year after introducing its breast cancer diagnosis AI solution, 'Lunit Insight MMG,' into actual medical practice at the ‘2024 Radiological Society of North America (RSNA 2024)’ held in Chicago, USA, from the 1st to the 4th.

The research was conducted at Sweden's largest private hospital, Capio St. G?ran Hospital. In June last year, St. G?ran Hospital became the first in the world to implement AI in place of one of the two radiologists recommended by Europe's ‘Double Reading’ system for breast cancer diagnosis, conducting real-world clinical use.

Dr. Karin Dembrower and her research team at St. G?ran Hospital compared and analyzed patient screening data from before AI introduction, July 2018 to March 2019, with data from after AI introduction, July 2023 to March 2024, covering over 55,000 screened patients.

The cancer detection rate (CDR) per 1,000 examinees increased by 15%, from 4.8 before AI introduction to 5.5 after. The recall rate, which summons patients for additional tests after suspicious findings, decreased by 11%, from 2.8% to 2.5%, relieving many patients from unnecessary anxiety while awaiting further test results.

The positive predictive value (PPV), indicating the proportion of actual cancers found among patients undergoing additional tests, rose significantly from 16.9% to 22.1%, and the false positive rate (FPR), where cases diagnosed as positive were ultimately negative, dropped from 89.6% to 78%. This means that replacing one doctor with AI in the double reading process greatly reduced unnecessary re-examinations while improving cancer detection accuracy.

Work efficiency also improved dramatically. After AI introduction, the reading time for medical staff decreased by 36%, allowing them to focus more on complex cases. Notably, while it previously took about 5 to 6 weeks for patients to receive mammography results, with AI, results can now be obtained immediately.

Dr. Karin Dembrower said, "Lunit's AI solution has already become a core element of the hospital's breast cancer screening system," adding, "Based on the real-world study results, other hospitals in Sweden and Europe will actively consider adopting AI." She also noted, "From the medical staff's perspective, the significant reduction in reading time after AI adoption is a very big advantage, enabling focus on more important tasks."

Seobum Seok, CEO of Lunit, stated, "At this year's RSNA conference, the role of AI in radiology was greatly emphasized, and through this study, we have concretely demonstrated the role of AI solutions that help both medical staff and patients," adding, "Lunit will continue to drive innovations that redefine the future of cancer screening."

St. G?ran Hospital, Sweden's largest private hospital with about 1,500 medical staff, performs approximately 78,000 mammographies annually. This study was presented directly by Dr. Karin Dembrower at RSNA 2024 and received significant global medical attention as a successful case of clinical AI application.